RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Pill vs. IV drip: major trial tests easier treatment for returning ovarian cancer
Disease control OngoingThis large, late-stage trial is testing whether taking pills (olaparib alone or with cediranib) works as well or better than standard intravenous chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned but still responds to platinum drugs. …
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New pill tested to fight returning gynecologic cancers
Disease control OngoingThis study is testing an oral medication called tazemetostat for people whose ovarian or endometrial cancer has returned after previous treatments. The drug aims to stop cancer cell growth and shrink tumors. Researchers are enrolling 62 patients to see how well the treatment work…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Race to control tough ovarian cancer: Three-Way drug showdown
Disease control OngoingThis study is testing which combination of three drugs works best to control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. It involves 444 patients and compares a standard two-drug combo agains…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat ovarian cancers in early trial
Disease control OngoingThis early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists test Immune-Boosting combo to fight returning ovarian cancer
Disease control OngoingThis study is testing if a two-drug combination works better than a single drug to control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. It compares a targeted pill (olaparib) alone to the pill plus an immunotherapy drug (tr…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New hope for tough ovarian cancers: Triple-Drug attack tested
Disease control OngoingThis study is testing whether combining two or three newer drugs works better than standard chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based drugs. It will involve about 120 women who have alr…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC